Ингибиторы дипептидил-пептидазы-4: новые надежды на преодоление эпидемии сахарного диабета типа 2

1. Turner RC Cull CA, Frighi V et al. The UK Prospective diabetes study group: glycemic control with diet< sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005–12.
2. Anderson JW, Kendall CW, Jenkins DJ et al. Importance of weight management in type 2 diabetes: rewiew with meta-analysis of clinical studies. J Am Coll Nutr 2003; 22: 331–9.
3. Viberti G, Kahn SE, Greene DA et al. A diabetes outcome progression trial (ADOPT). N international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002; 25: 1737–43.
4. Nauck MA, Homberger E, Siegel EG et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinpl Metab 1986; 63: 492–8.
5. Holst J. The physiology and pharmacology of incretins in type 2 diabetes. Diabetes Obes Metab 2008; 10 (Suppl. 3): 14–21.
6. Pi-Sunyer FX, Schweizer A, Mills D et al. Efficacy and tolerability of vildagliptin monotherapy in drug-nai.ve patients with type 2 diabetes. Diabetes REs Clin Pract 2007; 76: 132–8.
7. Rosenstock J, Baron MA, Dejager S et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 2007; 30: 217–23.
8. Ahren B, Gomis R, Standl E et al. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2874–80.
9. Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-nai.ve patients with typc 2 diabetes. Diabet Med 2007; 24: 955–61.
10. Fonseca V, Schweizer A, Albrecht D et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007; 50: 1148–55.
11. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007; 30: 890–5.
12. Garber AJ, Foley J, Banerji MA et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulfonylurea. Diabetes Obes Metab 2008; 10 (11): 1047–56.
13. Garber AJ, Schweizer A, Baron MA et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007; 9: 166–74.
14. Pospisilik JA, Martin J, Doty T et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 2003; 52 (3): 741–50.
15. Galvus®. Summary of Product Characteristics. Novartis Pharmaceuticals UK Ltd (20 February 2008). Available at: http://www.medicines.org.uk (Accessed April 2008).
16. Marfella R, Barbieri M et al. Effects of vildagliptin twice daily versus sitagliptin once daily on 24-hour acute glucose fluctuations. J Diab Compl 2009; in press.
17. Manucci E, Ognibene A, Cremasco F et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subject. Diabetes Care 2001; 4: 489–94.
18. Hinke SA, Kuhn-Wache K, Hoffman et al. Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide. Biochem Biophys Res Commun 2002; 291: 1320–8.